

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	04040/000L566-USO
-------	---	----	---	------------------------	-------------------

**Complete if Known**

Application Number	09/720,647-Conf. #3796
Filing Date	July 17, 2001
First Named Inventor	Ramachandran Murali
Art Unit	<del>N/A</del> 1631
Examiner Name	<del>Not Yet Assigned</del> LY

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
CPL	BA	EP-0 818 744-A2	01-14-1998	Proteus Molecular Design Limited		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.


**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
CPL	CA	Kellogg, Glen Eugene, et al., "Key, Lock, and Locksmith: Complementary hydropathic map predictions of drug structure from a known receptor-receptor structure from known drugs", J. Mol. Graphics, Vol. 10, No. 4, December 1992, pp. 212-217.	
	CB	Huang, Ziwei, et al., "Immunoglobulin Superfamily Proteins: Structure, Mechanisms, and Drug Discovery", Biopolymers, Vol. 43, No. 5, 1997, pp. 367-382.	
	CC	Zographos, Spyros E., et al., "The structure of glycogen phosphorylase b with an alkyl-dihydropyridine-dicarboxylic acid compound, a novel and potent inhibitor", Structure, Vol. 5, No. 11, November 15, 1997, pp. 1413-1425.	
	CD	Bohm, Hans-Joachim, "Computational Tools for Structure-Based Ligand Design", Progress in Biophysics and Molecular Biology, Vol. 66, No. 3, 1996, pp. 197-210.	
	CE	Murali, Ramachandran, et al., "Structure-Based Design of Immunologically Active Therapeutic Peptides", Immunologic Research, Vol. 17, No. 1/2, January 1998, pp. 163-169.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	5/16/05
-----------------------	--	--------------------	---------



PTO/SB/08a/b (08-03)  
Approved for use through 07/31/2008. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	09/720,647	
			Filing Date	July 17, 2001	
			First Named Inventor	Ramachandran Murali	
			Art Unit	1631	
			Examiner Name	C. D. Ly	
Sheet	1	of	1	Attorney Docket Number	04040/000L566-US0

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
CDC	AA	US-5,571,825	11-05-1996	Boschelli et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
CDC	BA	WO-98/49897-A	11-12-1998	SmithKline Beecham Corporation		
COL	BB	WO-97/34589-A	09-25-1997	President and Fellows of Harvard College		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
CDC	CA	WU, Bo Jack et al., "Selective Medium for Pseudomonas Cepacia Containing 9-chloro-9-(4-diethylaminophenyl)-10-phenylacridan and Polymyxin B Sulfate," XP002321547, Applied and Environmental Microbiology, 1984. (Abstract only)	
	CB	LOW, A I et al, "Phycomycosis of the Kidney Associated with a Transient Immune Defect and Treated with Clotrimazole," The Journal of Urology, June 1974, vol. 111, no. 6, pages 732-734.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	5/7/05
-----------------------	--	--------------------	--------